The expression of metallothioneins on imprint smears of prostate carcinoma: Correlation with clinicopathologic parameters and tumor proliferative capacity

Tumori

Volumn 93, Issue 2, 2007, Pages 189-194

  Athanassiadou, Pauline ^a   Bantis, Athanasios ^b   Gonidi, Maria ^a   Athanassiades, Peter ^a   Agelonidou, Eleni ^a   Grapsa, Dimitra ^a   Nikolopoulou, Polyxeni ^a   Patsouris, Efstratios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b University General Hospital   (Greece)

Author keywords

Immunocytochemistry; Ki 67; Metallothioneins; Prognostic factors; Prostate cancer

Indexed keywords

KI 67 ANTIGEN; METAL ION; METALLOTHIONEIN; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD SMEAR; CANCER CELL; CELL PROLIFERATION; DETOXIFICATION; DRUG BLOOD LEVEL; GENE EXPRESSION; GLEASON SCORE; HOMEOSTASIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE LINEAR REGRESSION ANALYSIS; OXIDATIVE STRESS; PARAMETER; PROPORTIONAL HAZARDS MODEL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY;

EID: 34249913192     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160709300213     Document Type: Article

References (42)

1. Theocharis SE, Margeli AP, Klijanienko JT, Kouraklis GP: Metallothionein expression in human neoplasia. Histopathology, 45: 103-108, 2004.
2. Theocharis S, Margeli A, Koutselinis A: Metallothionein: a multifunctional protein from toxicity to cancer. Int J Biol Markers, 18: 162-169, 2003.
3. Jasani B, Schmid KW: Significance of metallothionein overexpression in human tumours. Histopathology, 31: 211-214, 1997.
4. Dziegiel P: Expression of metallothioneins in tumor cells. Pol J Pathol, 55: 3-12, 2004.
5. Jin R, Huang J, Tan PH, Bay BH: Clinicopathological significance of metallothioneins in breast cancer. Pathol Oncol Res, 10: 74-79, 2004.
6. West AK, Stallings R, Hildebrand CE, Chiu R, Karin M, Richards RI: Human metallothionein genes: structure and functional locus at 16q13. Genomics, 8: 513-518, 1990.
7. Stennard FA, Holloway AF, Hamilton J, West AK: Characterization of six additional human metallothionein genes. Biochim Biophys Acta, 1218: 357-365, 1994.
8. Jin R, Chow VTK, Tan PH, Dheen T: Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis, 23: 81-86, 2002.
9. Quaife CJ, Findley SD, Erickson JC, Froelick GJ, Kelly EJ, Zambrowicz BP, Palmiter RD: Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. Biochemistry, 33: 7250-7259, 1994.
10. Stennard FA, Holloway AF, Hamilton J, West AK: Characterization of six additional human metallothionein genes. Biochim Biophys Acta, 1218: 357-365, 1994.
11. Cavigelli M, Kagi JH, Hunziker PE: Cell-and inducer-specific accretion of human isometallothioneins. Biochem J, 292: 551-554, 1993.
12. Jahroudi N, Foster R, Price-Haughey J, Beitel J, Gedamu L: Cell-type specific and differential regulation of the human metallothionein genes. Correlation with DNA methylation and chromatin structure. J Biol Chem, 265: 6506-6511, 1990.
13. Abdel-Magged A, Agrawal KC: Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Ther, 4: 199-120, 1997.
14. Cherian MG, Jayasurya A, Bay BH: Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res, 533: 201-209, 2003.
15. Moussa M, Kloth D, Peers G, Cherian MG, Frei JV, Chin JL: Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen. Clin Invest Med, 20: 371-380, 1997.
16. Zhang XH, Jin L, Sakamoto H, Takenaka I: Immunohistochemical localization of metallothionein in human prostate cancer. J Urol, 156: 1679-1681, 1996.
17. Henrique R, Jeronimo C, Hoque M, Nomoto S, Carvalho AL, Costa VL, Oliveira J, Teixeira MR, Lopes C, Sidransky D: MT1G Hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev, 14: 1274-1278, 2005.
18. Goyer R, Liu J, Waalks M: Cadmium and cancer of prostate and testis. Biometals, 17: 555-558, 2004.
19. Munoz E, Gomez F, Paz JI, Casado I, Silva JM, Corcuera MT, Alonso MJ: Ki-67 immunolabeling in pre-malignant lesions and carcinoma of the prostate. Histological correlation and prognostic evaluation. Eur J Histochem, 47: 123-128, 2003.
20. Bantis A, Giannopoulos A, Gonidi M, Liossi A, Aggelonidou E, Petrakakou E, Athanassiades P, Athanassiadou P: Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value. Cytopathology, 15: 25-31, 2004.
21. Claudio PP, Zamparelli A, Garcia FU, Claudio L, Ammirati G, Farina A, Bovicelli A, Russo G, Giordano GG, McGinis DE, Giordano A, Gardi G: Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2 and Ki-67 (MIB-1) in prostatic gland adenocarcinoma. Clin Cancer Res, 8: 1808-1815, 2002.
22. Mirtti T, Kallajoki M, Aaltonen M, Alanen K: Cyclin A and Ki-67 with DNA content in benign and malignant prostatic epithelial lesions. Anal Quant Cytol Histol, 23: 229-237, 2001.
23. Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M 3rd, Shipley WIJ, Hanks GE, Sandler HM: Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol, 22: 2133-2140, 2004.
24. Rubio J, Ramos D, Lopez-Gurrero JA, Iborra I, Collado A, Solsond E, Almenar S, Llombart-Bosch A: A. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol, 48: 745-751, 2005.
25. Athanassiadou P, Bantis A, Gonidi M, Liossi A, Aggelonidou E, Petrakakou E, Giannopoulos A: Telomerase expression as a marker in prostate cancer: correlation to clinicopathologic predictors. J Exp Clin Res, 22: 613-618, 2003.
26. Hsu SM, Raine L: Protein A, avidin and biotin in immunohistochemistry. J Histochem Cytochem, 29: 1349-1353, 1989.
27. Bantis A, Gonidi M, Athanassiades P, Tsolos Ch, Liossi A, Aggelonidou E, Athanassiadou AM, Petrakakou E, Athanassiadou P: Prognostic value of DNA analysis of prostate adenocarcinoma; Correlation to clinicopathologic predictors. J Clin Cancer Res, 24: 273-278, 2005.
28. Shimoda R, Achanzar WE, Qu W, Nagamine T, Takagi H, Mori M, Waalkes MP: Metallothionein is a potential regulator of apoptosis. Toxicol Sci, 73: 294-300, 2003.
29. McCluggage WG, Strand K, Abdulkadir A: Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors. Int J Gynecol Cancer, 12: 62-65, 2002.
30. Saga Y, Hashimoto H, Yachiku S, Tokumitsu M, Kaneko S: Immunohistochemical expression of metallothionein in human bladder cancer: correlation with histopathological parameters and patient survival. J Urol, 168: 2227-2231, 2002.
31. Tan Y, Sinnniah R, Bay BH, Singh G: Expression of metallothionein and nuclear size in discrimination of malignancy in mucinous ovarian tumours. Int J Gynecol Pathol, 8: 344-350, 1999.
32. Cai L, Wa'ng GJ, Xu ZL, Deng OX, Chakrabarti S, Cherian MG: Metallothionein and apoptosis in primary human hepatocellular carcinoma from northern China. Anticancer Res, 18: 4667-4672, 1998.
33. Jayasurya A, Bay BH, Yap WM, Tan NG: Correlation of metallothionein expression with apoptosis in nasopharyngeal carcinoma. Br J Cancer, 82: 1198-1203, 2000.
34. Dziegiel P, Forgacz J, Suder E, Surowiak P, Kormafel J, Zabel M: Prognostic significance of metallothionein expression in correlation with Ki-67 expression in adenocarcinomas of large intestine. Histol Histopathol, 18: 401-407, 2003.
35. Meskel HH, Cherian MG, Martinez VJ, Veinot LA, Frei JV: Metallothionein as an epithelial proliferative compartment marker for DNA flow cytometry. Mod Pathol, 6: 755-760, 1993.
36. Vallee BL, Falchuk KH: The biochemical basis of zinc physiology. Physiol Rev, 73: 79-118, 1993.
37. Cano-Gauci DF, Sarkar B: Reversible zinc exchange between metallothionein and the estrogen receptor zinc finger. FEBS Lett, 386: 1-4, 1996.
38. Jacob C, Maret W, Vallee BL: Control of zinc transfer between thionein, metallothionein and zinc proteins. Proc Natl Acad Sci USA, 95: 3489-3494, 1998.
39. Garrett SH, Sens MA, Shukla D, Flores L, Somji S, Todd JH, Sens DA: Metallothionein isoform 1 and 2 gene expression in human prostate: Downregulation of MT-IX in advanced prostate cancer. Prostate, 43: 125-135, 2000.
40. Hasumi M, Suzuki K, Matsui H, Koike H, Ho K, Yamanaka H: Regulation of metallothionein and zinc transporter expression in human prostate cancer cells and tissues. Cancer Lett, 200: 187-195, 2003.
41. Tohyama C, Suzuki JS, Homma S, Karasawa M, Kuroki T, Nishimura H, Nishimura N: Testosterone-dependent induction of metallothionein in genital organs of male rats. Biochem J, 317: 97-102, 1996.
42. Rao PS, Jaggi M, Smith D, Hemstreet GP, Balaji KC: Metallothionein 2A interacts with the kinase domain of PKCmu in prostate cancer. Biochem Biophys Res Commun, 310: 1032-1038, 2003.